Your browser doesn't support javascript.
loading
Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways "LEAN" working group.
Black, James H; Buckley, Donna; Velezis, Martha; Eldrup-Jorgensen, Jens; Serratore, Nina D; Gutierrez, Jorge A; Whatley, Eleni; Marmor, Rebecca A; Bertges, Daniel J; Tcheng, James E; Royce, Sara; Malone, Misti; Farb, Andrew; Secemsky, Eric A; Parikh, Sahil A; Smale, Joshua; Jaff, Michael R; White, Roseann; Wilgus, Rebecca W; Krucoff, Mitchell W.
  • Black JH; Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: jhblack@jhmi.edu.
  • Buckley D; Office of Cardiovascular Devices, Food and Drug Administration, Silver Spring, MD.
  • Velezis M; Office of Cardiovascular Devices, Food and Drug Administration, Silver Spring, MD.
  • Eldrup-Jorgensen J; Society of Vascular Surgery Patient Safety Organization, Chicago, IL.
  • Serratore ND; Cook Research, Inc, West Lafayette, IN.
  • Gutierrez JA; Duke University Medical Center/Duke Clinical Research Institute, Durham, NC.
  • Whatley E; Office of Cardiovascular Devices, Food and Drug Administration, Silver Spring, MD.
  • Marmor RA; Johns Hopkins University School of Medicine, Baltimore, MD.
  • Bertges DJ; University of Vermont Medical Center, Burlington, VT.
  • Tcheng JE; Duke University Medical Center/Duke Clinical Research Institute, Durham, NC.
  • Royce S; Office of Cardiovascular Devices, Food and Drug Administration, Silver Spring, MD.
  • Malone M; Office of Cardiovascular Devices, Food and Drug Administration, Silver Spring, MD.
  • Farb A; Office of Cardiovascular Devices, Food and Drug Administration, Silver Spring, MD.
  • Secemsky EA; Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA.
  • Parikh SA; Columbia University Irving Medical Center, New York, NY.
  • Smale J; Becton, Dickinson and Company, Franklin Lakes, NJ.
  • Jaff MR; Boston Scientific, Corporation, Inc, Marlborough, MA.
  • White R; Syntactx, New York, NY.
  • Wilgus RW; Duke University Medical Center/Duke Clinical Research Institute, Durham, NC.
  • Krucoff MW; Duke University Medical Center/Duke Clinical Research Institute, Durham, NC.
J Vasc Surg ; 78(5): 1313-1321, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37524153
Registry Assessment of Peripheral Interventional Devices (RAPID) initiated the Pathways Program to provide a transparent, collaborative forum in which to pursue insights into multiple unresolved questions on benefit-risk of paclitaxel-coated devices, including understanding the basis of the mortality signal, without a demonstrable potential biological mechanism, and whether the late mortality signal could be artifact intrinsic to multiple independent prospective randomized data sources that did not prespecify death as a long-term end point. In response to the directive, the LEAN-Case Report Form working group focused on enhancements to the RAPID Phase I Minimum Core Data set through the addition of key clinical modifiers that would be more strongly linked to longer-term mortality outcomes after peripheral arterial disease intervention in the drug-eluting device era, with the goal to have future mortality signals more accurately examined.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Año: 2023 Tipo del documento: Article